Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | IL1B | P01584 | 4/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31349498 | 0.87 | AR (0.36) | ARIL1B | |
| SCHEMBL31436451 | 0.85 | AR (0.37) | ARIL1B | |
| SCHEMBL31436484 | 0.84 | AR (0.46) | ARIL1B | |
| SCHEMBL31698277 | 0.81 | AR (0.37) | ARIL1B | |
| SCHEMBL31349503 | 0.81 | AR (0.33) | AR | |
| SCHEMBL31349563 | 0.80 | AR (0.32) | AR | |
| SCHEMBL25316359 | 0.77 | AR (0.40) | ARIL1BTNF | |
| SCHEMBL30507063 | 0.77 | AR (0.40) | ARIL1BTNF | |
| SCHEMBL25313086 | 0.77 | AR (0.40) | ARIL1BTNF | |
| SCHEMBL30507049 | 0.77 | AR (0.40) | ARIL1BTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743079-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015104-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2025015106-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |